Schrodinger, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Schrödinger reported Q2 2026 ACV of $29.6M (27% YoY growth) and total revenue of $58.9M (8% growth). Drug discovery revenue jumped to $23.0M from $13.9M YoY, driven by a $10M collaboration milestone from the Eli Lilly acquisition of Ajax Therapeutics. The company swung to $6.0M net income (vs. $43.2M loss YoY) primarily due to a $45.9M gain on fair value changes in equity investments from the Ajax deal completion. Full-year 2026 ACV guidance: $218–228M (10–15% growth). Schrödinger launched Bunsen, an agentic AI co-scientist, with strategic deployments at Bristol Myers Squibb and support from NVIDIA and Google Cloud.
Why this rating
Q2 results are solid (27% ACV growth, return to profitability) but heavily inflated by non-recurring Ajax milestone ($10M) and equity gains ($45.9M). Excluding these, operating performance is moderate. Bunsen launch and BMS deal are strategically promising but early-stage. At $1.1B market cap, ~$30M ACV quarterly is ~11% annualized—meaningful but not transformational. Cash position strong ($419M). Guidance of 10–15% ACV growth is respectable but below recent momentum.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.